Nicholas Alexander Livingston, PhD
Assistant Professor, Psychiatry
Biography
Dr. Livingston received his PhD from the University of Montana and completed his predoctoral internship at VA Boston Healthcare System (rotations: Alcohol and Drug Treatment Program, Substance Abuse Residential Rehabilitation Treatment Program, and Women’s Trauma Recovery Program). He subsequently completed the 2-year VA Interprofessional Advanced Fellowship in Addiction Treatment at VA Boston, with an emphasis in substance use disorder (SUD) and PTSD research and treatment. Dr. Livingston is currently a Principal Investigator in the National Center for PTSD, Behavioral Science Division, and Assistant Professor of Psychiatry at Chobanian and Avedisian School of Medicine. His clinical appointment is in the Alcohol and Drug Treatment Program, VA Boston Medical Center, JP. Primary clinical expertise includes evidence-based SUD and PTSD treatment, and patient centered adaptations to evidence-based care.
Primary research interests include substance use and disorder, treatment access and outcomes, and adverse events (e.g., overdose); the longitudinal course of trauma, PTSD, and interrelated psychiatric sequelae; and health disparities. Current funding supports examinations of the impacts of COVID-19 and medication for opioid use disorder (MOUD) policy changes on access to care and patient outcomes (e.g., relapse, mortality; PCORI COVID-2020C2-11081; PI: Livingston), the long-term impacts of combat and other traumas among OEF/OIF/OND veterans (W81XWH-22-S-TBIPH2; PIs: Marx & Bovin), and various studies focused on VA health services and patient outcomes. Current priorities include improving access to MOUD and treatment retention, substance use and relapse tracking using electronic medical record data (via Natural Language Processing and Large Language Models), modeling risk for acute and substance-attributable death among veterans with SUD, and identifying and addressing health disparities.
Dr. Livingston is also a primary or co-mentor on early career development awards (e.g., K, VA CDA-2) and core research training faculty for the Boston University NIMH T32, VA Medical Informatics Fellowship, VA Interprofessional Advanced Fellowship in Addiction Treatment, and other psychology training programs at VA Boston Healthcare System.
Education
- University of Montana, PhD
Publications
- Published on 10/31/2024
Livingston NA, Mandavia AD, Banducci AN, Loeffel LB, Hall RS, Maloney M, Roth CE, Fonda JR, Davenport M, Meng F, Hyde J, Stein M. Emergency department visits, inpatient hospitalizations, and non-fatal and fatal drug overdoses during COVID-19 among Veterans with opioid use disorder. J Stud Alcohol Drugs. 2024 Oct 31. PMID: 39480692.
Read at: PubMed - Published on 9/30/2024
Chang CJ, Fischer IC, Harper KL, Livingston NA, Depp CA, Norman SB, Pietrzak RH. Sexual orientation moderates the association between health care utilization-related factors and mental health service nonutilization among United States military veterans. Psychol Serv. 2024 Sep 30. PMID: 39347751.
Read at: PubMed - Published on 9/18/2024
Salim SR, Harper KL, Livingston NA, Feinstein BA, Messman TL. Bisexual minority stress as a risk factor for sexual violence-related posttraumatic stress disorder symptoms among bisexual+ women: A multilevel analysis. J Trauma Stress. 2025 Feb; 38(1):63-74. PMID: 39290082.
Read at: PubMed - Published on 7/8/2024
Jasuja GK, Wolfe HL, Reisman JI, Vimalananda VG, Rao SR, Blosnich JR, Livingston NA, Shipherd JC. Corrigendum: Clinicians in the Veterans Health Administration initiate gender-affirming hormone therapy in concordance with clinical guideline recommendations. Front Endocrinol (Lausanne). 2024; 15:1448887. PMID: 39040672.
Read at: PubMed - Published on 6/24/2024
Harper KL, Blosnich JR, Livingston N, Vogt D, Bernhard PA, Hoffmire CA, Maguen S, Schneiderman A. Trauma exposure, mental health, and mental health treatment among LGBTQ+ veterans and nonveterans. Psychol Trauma. 2024 Jun 24. PMID: 38913715.
Read at: PubMed - Published on 6/5/2024
LeBeau LS, White MC, Henke RM, Hyde J, Sarpong A, Weisberg RB, Livingston NA, Mulvaney-Day N. Considerations for Opioid Use Disorder Treatment From Policy Makers' Experiences With COVID-19 Policy Flexibilities. Psychiatr Serv. 2024 Nov 01; 75(11):1109-1116. PMID: 38835255.
Read at: PubMed - Published on 5/10/2024
Jasuja GK, Wolfe HL, Reisman JI, Vimalananda VG, Rao SR, Blosnich JR, Livingston NA, Shipherd JC. Clinicians in the Veterans Health Administration initiate gender-affirming hormone therapy in concordance with clinical guideline recommendations. Front Endocrinol (Lausanne). 2024; 15:1086158. PMID: 38800485.
Read at: PubMed - Published on 5/9/2024
Chang CJ, Livingston NA, Rashkovsky KT, Harper KL, Kuehn KS, Khalifian C, Harned MS, Tucker RP, Depp CA. A Scoping Review of Suicide Prevention Interventions for Lesbian, Gay, Bisexual, Transgender, Queer, and Other Sexual and Gender Minority Individuals. LGBT Health. 2025; 12(2):89-107. PMID: 38722250.
Read at: PubMed - Published on 4/3/2024
Wolfe HL, Vimalananda VG, Wong DH, Reisman JI, Rao SR, Shipherd JC, Blosnich JR, Livingston NA, Jasuja GK. Patient Characteristics Associated with Receiving Gender-Affirming Hormone Therapy in the Veterans Health Administration. Transgend Health. 2024 Apr; 9(2):151-161. PMID: 38694620.
Read at: PubMed - Published on 3/4/2024
Valentine SE, Gell-Levey IM, Godfrey LB, Livingston NA. The Associations Between Gender Minority Stressors and PTSD Symptom Severity Among Trauma-Exposed Transgender and Gender Diverse Adults. J Trauma Dissociation. 2024; 25(4):422-435. PMID: 38436077.
Read at: PubMed
View 49 more publications: View full profile at BUMC